Physician profile
Daniel Nathan Grant
NPI 1114377207
$1,975.39
in general payments reported to CMS, 2019-2025
20 companies · $31.01 in 2025
The $31.01 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $109 · 2021: $271 · 2022: $401 · 2023: $614 · 2024: $549 · 2025: $31.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.27 |
| Education | $209.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $487.93 | 2022-2024 | Enbrel, Tavneos, Otezla |
| Davol INC. | $255.91 | 2020-2021 | |
| Abbvie INC. | $208.86 | 2021-2024 | |
| Pfizer INC. | $189.28 | 2021-2024 | |
| Janssen Biotech, INC. | $175.11 | 2023-2024 | Tremfya |
| Ucb, INC. | $119.27 | 2022-2024 | Cimzia |
| Novartis Pharmaceuticals Corporation | $111.04 | 2021-2024 | |
| Glaxosmithkline, LLC. | $65.03 | 2023-2024 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $54.15 | 2022-2023 | Saphnelo |
| Aurinia Pharma U.S., INC. | $42.43 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.23 | 2023-2024 | |
| Sobi, INC | $38.50 | 2024 | |
| Horizon Therapeutics Plc | $37.62 | 2022-2023 | Krystexxa |
| Sandoz INC. | $33.19 | 2023 | Hyrimoz |
| Boston Scientific Corporation | $31.01 | 2025 | Innova Vascular |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.43 | 2022 | |
| Fresenius Kabi USA, LLC | $18.83 | 2023 | Idacio |
| Radius Health, INC. | $17.82 | 2024 | Tymlos |
| Kiniksa Pharmaceuticals International, Plc | $16.32 | 2024 | Arcalyst |
| Genentech USA, INC. | $14.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.